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INTRODUCTION
Human mitochondrial DNA (mtDNA) is a double-strand-
ed, 16.6-kb circular genome that codes 37 genes, all of which
are essential for the structural and functional maintenance of
the mitochondrial respiratory chain (1). So far, various patho-
genic mutations have been reported affecting mtDNA (2).
Among them, mutations in tRNA gene produce translation
defect and thus, produce global dysfunction in mitochondrial
respiratory chain. Both mitochondrial myopathy, encephalo-
pathy, lactic acidosis, and stroke-like episode (MELAS) and
myoclonic epilepsy and ragged-red fibers (MERRF) are caused
by such mechanism. In addition, they have common clinical
features including high serum lactate level, ragged-red fibers
(RRFs) on muscle biopsy, and overlapping neurological
findings such as myopathy and seizure. In MELAS and
MERRF, the mutations tend to cluster in some specific sites
(3), which enables the polymerase chain reaction-restriction
length polymorphism (PCR-RFLP) an effective strategy for
the molecular study. The main purpose of this study was to
evaluate pathological and molecular genetic features, and
thus, to approach its pathogenesis among Korean patients
with MELAS and MERRF. 
METHODS
Patients
Among 14 unrelated biopsy-proven patients with mito-
chondrial disease diagnosed by the authors, two MELAS and
two MERRF cases were selected for the study. All showed
typical clinical features of MELAS or MERRF with lactic
acidosis and RRFs on muscle biopsy. Muscle phosphorus32-
magnetic resonance spectroscopy was performed in 3 cases
and all showed a decrease in phosphocreatine (PCr)/inorganic
phosphate (Pi) ratio, which is typical of mitochondrial myo-
pathies (4). Before beginning of the study, the purpose and
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Histochemical and Molecular Genetic Study of MELAS and MERRF in
Korean Patients
Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episode
(MELAS) and myoclonic epilepsy and ragged-red fibers (MERRF) are rare dis-
orders caused by point mutation of the tRNA gene of the mitochondrial genome.
To understand the pathogenetic mechanism of MELAS and MERRF, we stud-
ied four patients. Serially sectioned frozen muscle specimens with a battery of
histochemical stains were reviewed under light microscope and ultrastructural
changes were observed under electron microscope. The polymerase chain reac-
tion-restriction fragment length polymorphism (PCR-RFLP) analysis was per-
formed and the tRNA genes were sequenced to confirm mutations. In two patients
with MELAS, strongly succinyl dehydrogenase positive blood vessels (SSVs) and
many cytochrome oxidase (COX) positive ragged-red fibers (RRFs) were ob-
served, and A3243G mutations were found from the muscle samples. In two
patients with MERRF, neither SSV nor COX positive RRFs were seen and
A8344G mutations were found from both muscle and blood samples. In the two
MERRF families, the identical mutation was observed among family members.
The failure to detect the mutation in blood samples of the MELAS suggests a low
mutant load in blood cells. The histochemical methods including COX stain are
useful for the confirmation and differentiation of mitochondrial diseases. Also,
molecular biological study using muscle sample seems essential for the confir-
mation of the mtDNA mutation. 
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I
II
III
IV
M/32
M/35
M/18
M/28
MELAS
MELAS
MERRF
MERRF
stroke, seizure,
myopathy, DM,
S-N deafness
stroke, myopathy, 
S-N deafness
myoclonic epilepsy,
myopathy, ataxia, 
dysarthria
myoclonic epilepsy,
S-N deafness, 
ataxia, dysarthria
48.9/not done
21.9/not done
118.6 /not done
22.9/1.2
mixed myopathic 
and neurogenic
myopathic
normal
normal
decreased PCr/Pi
decreased PCr/Pi
decreased PCr/Pi
not done
none; mother 
has DM 
unknown
mother, brother,
and mother’ s 
sister
mother
Table 1. Clinical profile of the patients with MELAS and MERRF
Case Gender/Age (yr) Syndrome Symptom/sign
Serum lactate/
pyruvate (mg%)
Electro-
myography
Muscle P
32 MRS Affected family
MELAS; myopathy, encephalopathy, lactic acidosis and stroke-like episode, MERRF; myoclonic epilepsy with ragged red fibers, DM; diabetes melli-
tus, S-N; sensorineural, P
32 MRS; phosphorus
32 magnetic resonance spectroscopy, PCr; phosphocreatine, Pi; inorganic phosphate. 
MERRF
MELAS
T3271C
A3243G
Forward; 5′ -AGGACAAGAGAAATAAAGGC-3′
Backward; 3′ -AATTCCAGTCTCCAAGTTAAGGAGAAGAAT-5′
Forward; 5′ -AGGACAAGAGAAATAAAGGC-3′
Backward; 3′ -ATGCGTTTCCGGGGTTGCAC-5′
initiation at 94°C for 1 min, 30 cycles
of denaturation (94°C for 15 sec),
annealing (55°C for 15 sec), and
extension (72°C for 30 sec), and final
extension at 72°C for 7 min.
170 bp
T3291C Forward; 5′ -AACTTAAAACTTTACAGTCAGAGGTTGGAT-3′
Backward; 3′ -TGGAATCGAGAGCGGTAGCG-5′
309 bp
A8344G Forward; 5′ -AGCCCACTGTAAAGCTAACT-3′
Backward; 3′ -GGTTGTGCCGAAATGTCACTTTACGGGGTT-5′
83 bp
294 bp
Table 2. Primers, PCR reactions, and the resultant size of the PCR products for PCR-RFLP
Type Site Primers PCR reaction PCR product
MELAS; mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episode, MERRF; myoclonic epilepsy with ragged-red fibers.
T8356C Forward; 5′ -AGCCCACTGTAAAGCTAACT-3′
Backward; 3′ -ATCTCACTTTACGGGGTTGATTTATGATGGCA-5′
97 bp
G8363A Forward; 5′ -AGATTAAGAGAACCAACACCTCTTTTACA-3′
Backward; 3′ -CCGGGTGGTATTAATGGGGG-5′
87 bp
initiation at 94°C for 4 min, 35 cycles
of denaturation (94°C for 30 sec),
annealing (45°C for  30 sec), and
extension (72°C for 1 min), and final
extension at 72°C for 7 min.
the extent of the experiment was explained to the patients
and their family members, and written consents were obtained.
Detailed clinical and laboratory features of the cases are shown
in Table 1.
Pathological study
Muscle samples were obtained from biceps muscles by
open biopsy, frozen immediately in liquid nitrogen-cooled
isopentane, and stored at -70℃ until used. Fresh frozen
blocks of biopsied muscle were sectioned at 10  m thick-
ness, processed for modified Gomori-trichrome (MGT), suc-
cinyl dehydrogenase (SDH), ATPase at pH 4.3, and cyto-
chrome oxidase (COX), and were finally reviewed under light
microscope. For electron microscopy, the samples were fixed
with 2% glutaraldehyde and embedded in epoxy resin accord-
ing to the standard procedure. Semithin 1  m thick resin
sections were stained with toluidine blue for light micro-
scopy. Ultrathin sections (60 nm thick) were cut with dia-
mond knives on an ultramicrotome (REICHERT SUPER-
NOVATM, Leica, Germany), double stained with uranyl
acetate and lead citrate, and examined under electron micro-
scope (GEM1200EX-2TM, JEOL, Japan).
PCR-RFLP analysis
Since about 80% of the reported cases are caused by
A3243G transition (5), 10% by T3271C transition (6) and
rarely by T3291C (7) and A3260G (8) of the mtDNA, the
PCR-RFLP analysis was designed to detect A3243G,
T3271C, and T3291C in MELAS cases (Table 2, 3). In
MERRF, more than 90% of the cases have A8344G muta-Histochemical and Molecular Genetic Study of MELAS and MERRF 105
tion (9) and other reported cases also cluster at tRNALys gene
(T8356C (10), G8363A (11)). So, in cases with MERRF,
the PCR-RFLP was designed to detect A8344G, T8356C,
and G8363A mutations (Table 2, 3).
The DNA was extracted from the whole blood and muscle
samples as described previously (12, 13). Eppendorf Master-
cycler 5330 (Eppendorf Co., U.S.A.) machine was used for
PCR. The total volume of PCR reaction was 25.0  L, which
consists of 2.5  L of ×10 reaction buffer, 2.0  L of 10 mN
dNTPs, 2.5  L of each primers, 0.2  L of Ex Taq polymerase
(TaKaRa, Japan), 1  L of DNA template, and 14.3  L of
distilled water. The primers, thermal cycling conditions and
resultant size of the PCR products are summarized in Table 2
and 3. The electrophoresis was performed on 4% 1:3 NuSieve
agarose gel (FMC, U.S.A.) with an addition of 10  L of ethid-
ium bromide (EtBr) in 0.5×TAE buffer solution (0.04 M
Tris-acetate, 0.001 M EDTA, pH 8.0). The 3  L of PCR-
RFLP product was loaded with the 2  L of loading buffer
and run at 100 V for 30 min.
DNA sequencing and analysis
Our strategy of DNA sequencing for MELAS was first to
analyze the sequence of tRNALeu(UUR) gene, and then shift to
other areas reported to be associated with MELAS (tRNAPhe,
tRNAVal, tRNACys, COX III and ND5 (14-18)). In case of
MERRF, sequence analysis was first performed for tRNALys
gene.
The primers for amplification of tRNALeu(UUR) in MELAS
cases were 5′ -CCAGGTCGGTTTCTATCTAC-3′ and 5′ -AG
AGTTTTATGGCGTCAGCG-3′ . The primers for tRNALys
in MEERF cases were 5′ -AACCAAACCACTTTCACCGC-
3′ and 5′ -ATGGGCTTTGGTGAGGGAGG-3′ . The total
volume of reaction was 50  L, consisting of 5.0  L of ×10
reaction buffer, 4.0  L of 10 mM dNTPs, 5  L of each pri-
mers, 0.8  L of Ex Taq polymerase (TaKaRa, Japan), 5  L
of DNA template, and 24.2  L of distilled water. The ther-
mal cycling conditions were initiation at 94℃ for 1 min,
35 cycles of denaturation at 94℃ for 15 sec, anealing at 55
℃ for 15 sec, and extension at 72℃ for 1 min. Final exten-
sion at 72℃for 7 min was added at the end of the cycle.
The PCR product was then purified with MicroSpinTM
S-400 HR Column (Amersham Pharmacia Biotech, U.K.),
and the sequencing reaction was performed using BigDyeTM
Terminator Cycle sequencing kit (PE Applied Biosystems,
U.S.A.). The total volume of the reaction was 20  L, which
includes 8  L of BigDye Terminator (BDT), 2  L of primers,
and 8  L of purified PCR product. The thermal cycling condi-
tions were initiation at 96℃for 10 sec and 25 cycles of denat-
uration at 96℃ for 10 sec, annealing at 50℃ for 5 sec, and
extension at 60℃ for 4 min. Then, the product was purified
with MicroSpinTM S-200 column (Amersham Pharmacia
Biotech, U.K.) and analyzed by electrophoresis in 1% agarose.
The automated sequencing was performed with ABI Prism
377 (PE Applied Biosystems, U.S.A.). Two microliters of
loading buffer was added to the product, denatured at 95℃
MELAS
MERRF
A3243G ApaI 
(GGGCC/C)
10×RB (TOYOBO, L-buffer) 1  L
PCR product 8  L
Apa I (TOYOBO) 1  L
Wild-type; unchanged (294 bp)
Mutant; 183 bp+111 bp
T3271C AflII
(C/TTAAG)
10×RB (TOYOBO, M-buffer) 1  L
PCR product 8  L
Afl II (TOYOBO) 1  L
Wild-type; unchanged (170 bp)
Mutant; 140 bp+30 bp
T3291C BamHI 
(G/GATTC)
10×RB (TOYOBO, H-buffer) 1  L
PCR product 8  L 
Bam HI (TOYOBO) 1  L
Wild-type; unchanged (309 bp)
Mutant; 280 bp+29 bp
A8344G BglI
(GCCNNNN/NGGC)
10×RB (TOYOBO, H-buffer) 1  L
PCR product 8  L
Bgl I (TOYOBO) 1  L
Wild-type; unchanged (83 bp)
Mutant; 53 bp+30 bp
G8363A SnaBI 
(TAC/GTA)
10×RB (BM, M-bufffer) 1  L
PCR product 8  L
Sna BI (BM) 1  L
Wild-type; unchanged (87 bp)
Mutant; 57 bp+30 bp
T8356C XbaI
(T/CTAGA)
10×RB (TaKaRa, M-bufffer) 1  L
bovine serum albumin 1  L
PCR product 7  L 
Xba I (TaKaRa) 1  L
Wild-type; unchanged (97 bp)
Mutant; 67 bp+30 bp
Table 3. Restriction enzyme digestion reactions used in the study
Type Site
Restriction enzyme
(cut sequence)
Composition
(total volume; 10  L)
Result
MELAS; mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episode, MERRF; myoclonic epilepsy with ragged-red fibers, RB;
reaction buffer. All restriction enzyme digestion reaction were performed overnight at 37°C.106 D.-S. Kim, D.-S. Jung, K.-H. Park, et al.
for 2 min, and 1.5  L of the solution was loaded on 4.25%
polyacrylamide (acrylamide: bis=29:1), 6 M urea gel. The
electrophoresis was performed for 10 hr with  ‘Seq Run 48E-
1200’ Run module using 48 cm WTR plate. Then, Gel
Image file was reviewed with minimizing the interference
between samples. Finally, sequence data were analyzed with
GENETYX-MAC program, comparing with the Anderson’ s
standard mtDNA sequence (1) and the suspected site of point
mutation was confirmed by manual inspection of the elec-
tropherogram.
RESULTS
Histochemical study
The proportion of RRFs judged by SDH stain was 15%
and 12% in cases with MELAS (cases I and II) and 5% and
1% in cases with MERRF (cases III and IV). In each case
with MELAS, strongly SDH-positive blood vessels (SSVs)
were observed (Fig. 1). In the cases with MELAS, some RRFs
had focally increased COX activities (20% among RRFs in
C D
A B
Fig. 1. Important pathological findings of the cases. (A) Ragged-red fiber in case I. Modified Gomori-trichrome stain,×200. (B)
Ragged-red fibers in case II. Succinyl dehydrogenase (SDH) stain,×40. (C) Strongly succinyl dehydrogenase-positive blood vessel
(SSV) in case I, ×100, arrow. (D) Electron microscopic finding. Abnormal proliferation of mitochondria with paracristaline inclusions in
case III, ×20,000.Histochemical and Molecular Genetic Study of MELAS and MERRF 107
case I and 15% in case II), while many other RRFs showed
decreas-ed or normal COX activities (Fig. 2). In contrast, all
RRFs showed either decreased or normal COX activities in
the cases with MERRF, and no RRF with a focal increase in
COX activity was observed (Fig. 3).
PCR-RFLP and sequence analysis of MELAS 
(cases I and II)
In DNA form the blood, no mutation was found in PCR-
RFLP for A3243G, T3271C, and T3291C in each case. Also,
automated sequencing for tRNALeu(UUR), tRNAPhe, tRNAVal,
tRNACys, COX III, ND5, and tRNASer genes revealed normal
sequences. However, in DNA from the muscle, treatment
with the restriction enzyme ApaI showed an abnormal diges-
tion pattern on PCR-RFLP and proved to have A3243G
mutation on subsequent DNA sequencing (Fig. 4, 5).
PCR-RFLP and sequence analysis of MERRF 
(cases III and IV)
In each case, PCR-RFLP analysis with both blood and
muscle DNA samples revealed an abnormal BglI digestion
pattern and were finally confirmed to have an A8344G muta-
tion (Fig. 6, 7). The abnormal bands from muscle samples
were clearer than those from venous blood on electrophore-
sis, suggesting there is a heavier mutant load in the muscle
than in the blood. Among family members of case IV, an
C
A B
Fig. 2. Histopathological findings of case I (MELAS). Three
ragged-red fibers are seen on modified Gomori-trichrome (A)
and succinyl dehydrogenase stain (B). One ragged-red fiber has
focal increase in cytochrome oxidase activity (upper right) while
the others show loss of cytochrome oxidase activities (C). A:
modified Gomori-trichrome stain,×100. B: succinyl dehydroge-
nase stain,×100. C: cytochrome oxidase stain,×100.   : ragged-
red fibers
*
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* *
*
*
* *
*108 D.-S. Kim, D.-S. Jung, K.-H. Park, et al.
asymptomatic sister proved to have the same mutation on
PCR-RFLP with restriction enzyme BglI (Fig. 6).
DISCUSSION
The RRF is a pathological marker for the mitochondrial
disease, which is most readily identified by SDH stain on
frozen muscle biopsy, and represents proliferation of the abnor-
mal mitochondria in muscle fibers. It is well known that the
amount of the mutant mtDNA in RRF is bigger than that
of non-RRF muscle fibers in patients with mitochondrial
myopathies. However, the exact mechanism that determines
the amount of the mutant load in each muscle fiber is not
known (19, 20).
The COX activity in muscle fibers is determined by the
functional expression of the COX subunits in the mitochon-
drial inner membrane and thus, roughly correlates to the
amount of the normal mtDNA. Because type I muscle fibers
normally have more mitochondria than type II fibers, they
show relatively increased COX activity than type II fibers on
histochemical stain and appear as dark brown color while type
II fibers stain light brown. Although the RRFs in mitochon-
drial myopathies have increased number of mitochondria,
they are functionally abnormal harboring mutant mtDNA.
Thus many of RRFs show decreased or loss of COX activi-
ties depending on the amount of mutant mtDNA they have
(21). Interestingly, the COX activity of RRFs in MELAS is
known to be different from that of MERRF, and our study
also showed differential staining patterns of MELAS and
MERRF (22). This finding is most likely caused by the dif-
ferences in the expression of the COX subunit, and could be
regarded as the secondary change resulting from a different
pathogenetic mechanism between MELAS and MERRF.
One of the important facts on COX immunohistochemistry
is that the reduced or loss of COX activity does not necessar-
ily mean the presence of mtDNA mutation. Because COX
is encoded by three mitochondrial (COX I, II, and III) and
nine nuclear genes (COX IV, Va, Vb, VIa, VIb, Vic, VIIa,
VIIb, VIIc and VIII), its activity also can be altered by the
294 bp
MM
UC
PC
Fig. 4. The results of RFLP analysis using restriction enzyme Apa I
for the detection of A→G transition at nucleotide position 3243 in
cases I and II (MELAS). In mutants, treatment with the restriction
enzyme Apa I produce two small fragments (183 bp and 111 bp)
instead of single 294 bp band. In both cases, abnormal digestion
pattern was identified only in muscle (M), but not in blood (B). M;
molecular marker, PC; positive control, NC; negative control, U;
uncut (undigested) PCR product, C; cut (digested) PCR product. 
UC
NC
UC
I(M)
UC
II(M)
UC
I(B)
UC
II(B)
183 bp
111 bp
A B
Fig. 3. Histopathological finding in case III (MERRF). Two ragged-red fibers are seen in succinyl dehydrogenase stain (A). On cyto-
chrome oxidase stain, one of the ragged-red fibers show complete loss of cytochrome oxidase activity (B, upper right). A: succinyl dehy-
drogenase stain,×200. B: cytochrome oxidase stain,×200.   : ragged-red fiber.
*
*
*
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mutations of the nuclear DNA encoding the COX subunits,
and other nuclear regulatory genes for COX (ex. SURF1)
(23, 24). In this regard, the results of a recent study on the
immunohistochemistry using COX subunits is noteworthy,
where they found selective loss or reduction of COX I and
II subunit activities in patients with known mtDNA muta-
tions, while reduced staining of all subunits were observed
in patients with probable nuclear DNA defects (25). Thus,
this technique would be useful for the differentiation of mito-
chondrial disease either into mtDNA defect or nuclear DNA
defect, although further study seems to be needed in order
to confirm its usefulness.
The SSV is another important histological finding unique-
ly seen in MELAS (26). The presence of SSV represents the
affection of the vascular smooth muscle cells in MELAS and
thought to be responsible for the stroke-like episode in this
disease (26). 
The A3243G mtDNA mutation in MELAS was first re-
ported by Goto et al. in 1990 (5), and is responsible for about
80% of the cases. Until now, most of the known MELAS
mutations are concentrated on the tRNALeu(UUR) gene, even
though there are some case reports affecting other genes in
mtDNA (14-18). Same frequencies of common MELAS
mutations also seem to apply among Korean patients with
MELAS, because 7 patients with A3243G mutation and
one with T3271C out of 10 patients with MELAS had been
identified in a study using blood sample (27).
In our cases of MELAS, the mutation was not found from
Fig. 5. The result of the automated sequencing in the case II
(MELAS). A: The blood sample showed normal sequence at
nucleotide position 3243 (arrowhead). B: The muscle sample of
the same patient shows A to G transition at the same site
(arrow) in the tRNA
Leu gene.
G A T GGC A G A G CCCGGT AAT C G
40
nt 3243
16 150
G A T GGC A GGGCCCGGT AAT C G
130
A
140
A
B
Fig. 7. The result of the automated sequencing in the case IV
(MERRF). The electropherogram shows A to G transition at the
nucleotide position 8344 (arrow) in the tRNA
Lys gene.
AAGTTAAAGATTAAGAGAGCCAACACCTCTTTACAGTGAAAT
140 150 160
A
8344
170 180
I
Family A
Family A Family B
83 bp
Family B
12
12 12
12
34 5678 1 2
M
P N III-1 II-5 II-1 II-2 II-3
MBMBBMBB
3
II
I
II
III
53 bp
30 bp
Fig. 6. Results of RFLP analysis using the restriction enzyme Bgl I
for the detection of A→G transition at nucleotide position 8344
in MERRF families (families A and B). In mutants, treatment with
the restriction enzyme Bgl I produce two small fragments (53 bp
and 30 bp) instead of single 83 bp band. The dark circles and
squares represent affected individuals. The probands are III-1
in family A (case III) and II-1 in family B (case IV). In probands,
both whole blood (B) and muscle (M) show abnormal digestion
pattern. In the mother of proband in family A (II-5), who also has
myoclonic epilepsy and muscle weakness, shows same diges-
tion pattern as in the proband. In family B, asymptomatic broth-
er (II-2) and sister (II-3) of the proband (II-1) were tested and
the sister shows same digestion pattern as in the proband. M;
muscle, B; blood, P; positive control, N; negative control.110 D.-S. Kim, D.-S. Jung, K.-H. Park, et al.
the blood DNA samples, but from the muscle samples. Thus,
it is assumed that an exclusion of the MELAS mutation with
a blood sample in clinically suspected cases could mislead
the diagnosis. According to a report, the A3243G MELAS
mutation can be found in about 50% of the cases when blood
samples are used for PCR-RFLP (28). This is thought to be
the result of the rapidly replicating ability of the blood cells,
which will gradually eliminate the leukocytes with a higher
mutation load (28). Interestingly, the A3243G mutations
also have been found among different clinical phenotypes,
including maternally inherited diabetes mellitus and deafness
(MIDD) (29), progressive external ophthalmoplegia (PEO)
(30), mitochondrial myopathy (31), and Leigh syndrome (32).
Also, there is a report documenting the different mutant
mtDNA ratio among different phenotypes of the A3243G
mutation, suggesting the clinical phenotypes may be deter-
mined by the mutant load (33).
The mtDNA mutations causing MERRF are known to be
more homogenous than in MELAS. The A8344G mutation,
first reported by Shoffner et al. (9), is responsible for more
than 90% of the cases of MERRF, and the T8356C (10) and
G8363A (11) mutations were found in the rest of the cases.
Also, in Korea, all of the molecular genetically confirmed
cases had A8344G mutations (34, 35). Thus, the MERRF
mutations are concentrated exclusively on the tRNALys gene
so far. Both of our MERRF cases clearly had a family history
of maternal inheritance pattern typical of mitochondrial dis-
orders, and the T8344C mutations were found both in PCR-
RFLP and automated sequencing targeted for the tRNALys
gene. Also, the mutations were readily identifiable in blood
samples although the amount of the mutant DNA is less in
blood samples than in muscle samples. Unlike the MELAS,
there is a clear relationship in the amount of mutation be-
tween muscle tissue and blood cells in MERRF and this may
represent the different pathogenetic mechanism between
them (36, 37). In case IV, PCR-RFLP for family members
revealed the same mutation in an asymptomatic sister. Accord-
ing to Larsson et al., the same mtDNA mutations are found
in a half of the siblings when the amount of the mutant DNA
of the mother is 10-33%, and all the siblings will have the
mutation when the amount of maternal mutant DNA is 43-
73% in MERRF (36). The mother of case IV reportedly was
unambulatory because of a profound muscle weakness when
she was alive, and so, it is assumed that the amount of mutant
DNA should be big enough to inherit the disease to some
of her siblings, according to the  “bottle neck hypothesis” in
mtDNA segregation (37, 38). The A8344G MERRF muta-
tion is located at the T C loop of the tRNALys gene, and dif-
ferent phenotypes have been reported as in A3243G MELAS
mutation (39, 40). The A8344G mutation in the tRNALys
gene affects the translation of lysine, and thus, produce the
defect in protein synthesis (ex. ND5) (41). Following the gene
dosage effect, the symptoms tend to be more severe when
there is a heavier mutant load in MERRF (42). 
In conclusion, both MELAS and MERRF are caused by
point mutations of the tRNA gene of the mitochondrial ge-
nome and have some common clinical findings despite many
different aspects. Careful histochemical evaluation using
frozen muscle tissue is important for the confirmation, dif-
ferentiation and characterization of the mitochondrial diseases.
In addition, the muscle tissue is essential for the molecular
biological diagnosis and research of the mitochondrial dis-
eases. 
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